🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
ABE
$ABEO
🔒 US EquitiesAbeona Therapeutics Inc.
AVG HISTORICAL GAP
-0.10%
MAX GAP RECORD
-18.36%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $ABEO
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$ABEO
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 11, 2026 Earnings Release 2026-11-11 (BEFORE OPEN (07:00)) | 🔮 UPCOMING 🔒 |
| Aug 13, 2026 Earnings Release 2026-08-13 (BEFORE OPEN) |
-18.36%
|
| May 13, 2026 Earnings Release 2026-05-13 (BEFORE OPEN) |
+2.29%
|
| Mar 17, 2026 Earnings Release 2026-03-17 (BEFORE OPEN) |
-3.43%
|
| Nov 12, 2025 Earnings Release 2025-11-12 (BEFORE OPEN) |
+8.63%
|
| Aug 14, 2025 Earnings Release 2025-08-14 (BEFORE OPEN) |
+4.42%
|
| May 15, 2025 Earnings Release 2025-05-15 (BEFORE OPEN) |
-0.56%
|
| Mar 20, 2025 Earnings Release 2025-03-20 (BEFORE OPEN) |
+3.08%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
4.3%
Bullish Gaps (8)
Bearish Gaps (3)
Neutral / Flat (3)
📖 Intelligence Summary
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗